- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01167634
University Of Pennsylvania Weight Loss Study
This is a 4-arm, randomized controlled trial to evaluate the effectiveness of financial incentives to motivate and sustain long-term weight loss. The study will recruit eligible employees at a large health management company to participate in a 6-month weight loss program and have weight measurements for an additional 3-month follow-up period. The primary outcome measure in this randomized controlled trial will be pounds of weight lost. The experimental groups will include variations of deposit contracts (participants put their own money at risk, and lose that money if they fail to achieve their weight loss goal) and fixed payments. The use of deposit contracts is a powerful mechanism for inducing behavior change that is based on loss aversion, a psychological concept first described by Nobel Prize winner Daniel Kahneman and Amos Tversky in 1979. A deposit contract takes advantage of the fact that people typically feel the pain of a loss more than the pleasure of a gain, increasing ones motivation to reach a goal.
The study hypotheses are 1) mean weight loss will be greater in all intervention groups compared to the control group by the end of 24 weeks; and 2) individuals in the intervention groups will have a lower mean weight at the end of the 3-month follow-up period than individuals in the control group.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- University of Pennsylvania
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Aged 18 to 70 (inclusive)
- BMI between 30 and 50 (inclusive)
Exclusion Criteria:
- Inability to consent
- No known Illiteracy and/or inability to speak, read, and write English
- Participation in another weight loss program
- Participation in another research study
- Current treatment for drug or alcohol use
- Consumption of 5 alcoholic drinks per day
- Myocardial infarction or stroke within the past 6 months
- Uncontrolled hypertension (defined as BP170 mm Hg systolic or BP110 mm Hg diastolic)
- Current addiction to prescription medicines or street drugs
- Serious psychiatric diagnoses (severe depression, schizophrenia)
- Pregnancy
- Diabetic and using any medicine besides metformin to control blood sugars
- Metastatic cancer
- Unstable medical conditions that would likely prevent the subject from completing the study
- Previous diagnosis of an eating disorder
- History of unsafe weight loss behaviors such as binging or the use of laxatives
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Aucune intervention: 1
|
|
Expérimental: 2
Deposit contract with a 1:1 match
|
Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount equal to deposited amount.
Final weigh-in at 36 weeks with no financial incentive or deposit made.
|
Expérimental: 3
Deposit contract with a 2:1 match
|
Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount twice the amount equal to deposited amount.
Final weigh-in at 36 weeks with no financial incentive or deposit made.
|
Expérimental: Experimental 4
Deposit contract with no match
|
Daily weigh-in for 24 weeks and if each daily goal met the daily deposit amount is paid back.
Final weigh-in at 36 weeks with no financial incentive or deposit made.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change in Weight
Délai: 24 Weeks
|
Change in weight between baseline and 24 weeks
|
24 Weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: George Loewenstein, PhD, Carnegie Mellon University
- Chaise d'étude: Kevin G. Volpp, MD, PhD, University of Pennsylvania
- Directeur d'études: Heather Schofield, MS, Harvard University
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 813407
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Deposit contract with a 1:1 match
-
Coopervision, Inc.Complété
-
Coopervision, Inc.Complété
-
Coopervision, Inc.Complété
-
Johnson & Johnson Vision Care, Inc.ComplétéErreur de réfractionRoyaume-Uni
-
Johnson & Johnson Vision Care, Inc.Complété
-
Roswell Park Cancer InstituteRetiré
-
Bausch & Lomb IncorporatedComplétéUtilisation habituelle de lentilles de contact souplesÉtats-Unis
-
Coopervision, Inc.Complété
-
Johnson & Johnson Vision Care, Inc.Complété
-
Johnson & Johnson Vision Care, Inc.Complété